CA-MIRO
28.4.2022 13:02:12 CEST | Business Wire | Press release
Miro , the online platform accelerating innovation through visual collaboration, today announced Miro Next , an all-virtual event revealing the next big thing for hybrid teams through the latest product and partner developments from the company. Miro Next will take place on May 18, 2022, at 8am PST / 5pm CEST and is purposefully designed to empower global teams to do more together.
Everyone is looking for new ways to succeed and thrive in today’s hybrid work environments. Some of the secrets to success include meetings that are more inclusive and interactive – blurring the lines between in-person and the virtual experience. Companies will need custom integrations between critical applications to help drive productivity and simplify the user experience, and more and more organizations will adopt agile practices that increase teamwork and speed innovation. Miro Next will explore these strategies, along with a host of updates on product features and enhancements, all designed to help organizations make hybrid work.
The event will kick off with a keynote presentation by Varun Parmar, Miro’s Chief Product Officer. Joined onstage with Miro partners and featured speakers, including Jeetu Patel of Cisco and Megan Cook of Atlassian, Parmar will show how Miro’s digital whiteboard is just the beginning of the future of visual collaboration.
“Miro Next will help us rediscover how to put people at the center of hybrid work, and in doing so, drive deeper engagement and collaboration among teams,” said Parmar. “I hope that teams all around the world will join us for this one-of-a-kind experience in just a few weeks.”
Miro Next will also feature a presentation led by Thor Mitchell, Miro’s Head of Product, Developer Platform, giving attendees an up-close-and-personal look at the next generation of Miro’s Developer Platform, and why it’s the perfect product to create an integrated collaboration experience that’s quick, easy, and seamless. The Miro Developer Platform was created three years ago to give any individual or enterprise the ability to build plugins and third-party integrations, and embed live Miro boards into other apps using Miro’s open API and SDKs. The Miro Developer Platform unlocks new, custom workflows to enhance the collaborative experience. At Miro Next, Airtable, ClickUp and others will join Mitchell to show how the Miro Developer Platform has unlocked new ways to harness visual collaboration using Miro and what they’re planning in the future.
In addition to learning about the future of visual collaboration from Miro product leaders and partners, Miro Next attendees will get exclusive access to breakout sessions to share ideas, ask questions, and connect with other Miro users who are seeking new ways to co-create with their teams, both synchronously and asynchronously. Miro Next breakout sessions include:
- The Road to Accessibility: A Collaborative Journey - Join Phil Strain, Miro Lead Product Manager for Accessibility and Design, and Sheri Byrne-Haber, VMWare Senior Staff Architect for Accessibility, to explore how an inclusive mindset can be a game-changer when it comes to company and end-user engagement.
- The Hybrid Workplace: Securing and Managing Collaboration In This New Way of Working - This thought leadership panel will include industry experts from Miro, Netskope, and Onna, sharing their top insights and practices for securing and managing hybrid workforces, while creating frictionless environments that help drive collaboration and creativity.
- Connected and Aligned: Your Hybrid Team in Miro - Join Miro’s team of customer education experts to learn how to use Miro features and skills to include all voices in collaborative work and create a one-stop Miro board for teams to gather information, share resources, and align expeditiously on what’s most important.
Miro Next will help all teams jump from “what now?” to “what’s next?” and explore their collaborative potential. Be among the first to preview new Miro features and get a sneak peek into the modern visual collaboration ecosystem:
- WHEN : May 18, 2022, 8 am PT/ 5 pm CET
- WHAT : One highlight-filled keynote session (60 minutes) and three, exclusive breakout sessions (60 minutes each)
- HOW : It’s virtual! RSVP for free at miro.com/next
About Miro
Miro is an online, visual collaboration platform designed to unlock creativity and accelerate innovation among teams of all kinds. The platform’s infinite canvas enables teams to lead engaging workshops and meetings, design products, brainstorm ideas, and more. Miro, co-headquartered in San Francisco and Amsterdam, serves more than 30M users worldwide, including 99% of the Fortune 100. Miro was founded in 2011 and currently has more than 1,400 employees in 10 hubs around the world. To learn more, please visit https://miro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005447/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom